Listed

Pfizer Inc: Form 10-Q for the period ended Jul 2, 2023

Filed with the SEC on Aug 9, 2023 and accepted by EDGAR at Aug 9, 2023, 16:11 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2023-07-02. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2023-04-03 to 2023-07-02$12.73bnus-gaap:Revenues
Revenue6 months2023-01-01 to 2023-07-02$31.02bnus-gaap:Revenues
Cost of revenue3 months2023-04-03 to 2023-07-02$3.24bnus-gaap:CostOfGoodsAndServicesSold
Cost of revenue6 months2023-01-01 to 2023-07-02$8.12bnus-gaap:CostOfGoodsAndServicesSold
Selling, general and administrative3 months2023-04-03 to 2023-07-02$3.50bnus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative6 months2023-01-01 to 2023-07-02$6.91bnus-gaap:SellingGeneralAndAdministrativeExpense
Interest expense3 months2023-04-03 to 2023-07-02$508.0mus-gaap:InterestExpense
Interest expense6 months2023-01-01 to 2023-07-02$826.0mus-gaap:InterestExpense
Income tax3 months2023-04-03 to 2023-07-02−$71.0mus-gaap:IncomeTaxExpenseBenefit
Income tax6 months2023-01-01 to 2023-07-02$644.0mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2023-04-03 to 2023-07-02$2.33bnus-gaap:NetIncomeLoss
Net income6 months2023-01-01 to 2023-07-02$7.87bnus-gaap:NetIncomeLoss
Diluted EPS3 months2023-04-03 to 2023-07-02$0.41us-gaap:EarningsPerShareDiluted
Diluted EPS6 months2023-01-01 to 2023-07-02$1.38us-gaap:EarningsPerShareDiluted
Basic EPS3 months2023-04-03 to 2023-07-02$0.41us-gaap:EarningsPerShareBasic
Basic EPS6 months2023-01-01 to 2023-07-02$1.40us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2023-04-03 to 2023-07-025,713,000,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2023-01-01 to 2023-07-025,720,000,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2023-01-01 to 2023-07-02$4.0mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure6 months2023-01-01 to 2023-07-02$2.05bnus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Share repurchases6 months2023-01-01 to 2023-07-02$0us-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2023-07-02$2.63bnus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2023-07-02$73.35bnus-gaap:AssetsCurrent
Total assetsAt period end2023-07-02$220.17bnus-gaap:Assets
Current liabilitiesAt period end2023-07-02$34.65bnus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2023-07-02$120.88bnus-gaap:Liabilities
Long-term debtAt period end2023-07-02$61.36bnus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2023-07-02$3.56bnus-gaap:LongTermDebtCurrent
Shareholders' equityAt period end2023-07-02$99.02bnus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0000078003-23-000088. Last ingested by Listed: Nov 12, 2026, 18:08 ET. Listed shows no prices and gives no investment advice.